<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Neuromuscular Diseases</journal-id><journal-title-group><journal-title xml:lang="en">Neuromuscular Diseases</journal-title><trans-title-group xml:lang="ru"><trans-title>Нервно-мышечные болезни</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2222-8721</issn><issn publication-format="electronic">2413-0443</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">96</article-id><article-id pub-id-type="doi">10.17650/2222-8721-2012-0-4-28-35</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>LECTURES AND REVIEWS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ЛЕКЦИИ И ОБЗОРЫ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="ru">Плейотропный нейропротективный и метаболический эффекты актовегина</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Machicao</surname><given-names>Fausto</given-names></name><address><country country="RU">Russian Federation</country></address><email>fausto.machicao@med.uni-tuebingen.de</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Muresanu</surname><given-names>Dafin Fior</given-names></name><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name><surname>Hundsberger</surname><given-names>Harald</given-names></name><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name><surname>Pflüger</surname><given-names>Maren</given-names></name><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name><surname>Guekht</surname><given-names>Alla</given-names></name><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff4"/></contrib></contrib-group><aff id="aff1"><institution>Molecular Genetics and Diagnosis, Department of Internal Medicine IV, Otfried Müller Str. 10, University Hospital, D-72076, Тюбинген, Германия</institution></aff><aff id="aff2"><institution>Department of Neurosciences, University of Medicine and Pharmacy «Iuliu Hatieganu», Клуж-Напока, Румыния</institution></aff><aff id="aff3"><institution>Medical and Pharmaceutical Biotechnology IMC Krems, University of Applied Sciences Krems, Piaristengasse 1, A-3500, Кремс, Австрия</institution></aff><aff id="aff4"><institution>Neurology and Rehabilitation, Department of Neurology and Neurosurgery of the Russian State, Москва, Россия</institution></aff><pub-date date-type="pub" iso-8601-date="2012-11-21" publication-format="electronic"><day>21</day><month>11</month><year>2012</year></pub-date><volume>2</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>28</fpage><lpage>35</lpage><history><date date-type="received" iso-8601-date="2015-02-21"><day>21</day><month>02</month><year>2015</year></date><date date-type="accepted" iso-8601-date="2015-02-21"><day>21</day><month>02</month><year>2015</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2012, ., ., ., ., .</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2012, Machicao F., Muresanu D., Hundsberger H., Pflüger M., Guekht A.</copyright-statement><copyright-year>2012</copyright-year><copyright-holder xml:lang="en">., ., ., ., .</copyright-holder><copyright-holder xml:lang="ru">Machicao F., Muresanu D., Hundsberger H., Pflüger M., Guekht A.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://nmb.abvpress.ru/jour/article/view/96">https://nmb.abvpress.ru/jour/article/view/96</self-uri><abstract xml:lang="ru"><p/></abstract><kwd-group xml:lang="ru"><kwd>актовегин</kwd><kwd>метаболический эффект</kwd><kwd>механизм действия</kwd><kwd>нейропротекция</kwd><kwd>апоптоз</kwd><kwd>оксидативный стресс</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">1. Muresanu DF. Neuromodulation with pleiotropic and multimodal drugs – future approaches to treatment of neurological disorders. Acta Neurochir Suppl 2010;106:291–4.</mixed-citation><mixed-citation xml:lang="ru">Muresanu DF. Neuromodulation with pleiotropic and multimodal drugs – future approaches to treatment of neurological disorders. Acta Neurochir Suppl 2010;106:291–4.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">2. Labiche LA, Grotta JC. Clinical trials for cytoprotection in stroke. NeuroRx Jan. 2004;1(1):46–70.</mixed-citation><mixed-citation xml:lang="ru">Labiche LA, Grotta JC. Clinical trials for cytoprotection in stroke. NeuroRx Jan. 2004;1(1):46–70.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">3. Maas AI, Roozenbeek B, Manley GT. Clinical trials in traumatic brain injury: past experience and current developments. Neurotherapeutics 2010 Jan;7(1):115–26.</mixed-citation><mixed-citation xml:lang="ru">Maas AI, Roozenbeek B, Manley GT. Clinical trials in traumatic brain injury: past experience and current developments. Neurotherapeutics 2010 Jan;7(1):115–26.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">4. Bornstein NM. Stroke: practical guide for physicians. S. Karger AG; 2009.</mixed-citation><mixed-citation xml:lang="ru">Bornstein NM. Stroke: practical guide for physicians. S. Karger AG; 2009.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">5. Muresanu DF. Neuroprotection and neuroplasticity – a holistic approach and future perspectives. J Neurol Sci 2007 Jun 15;257(1–2):38–43.</mixed-citation><mixed-citation xml:lang="ru">Muresanu DF. Neuroprotection and neuroplasticity – a holistic approach and future perspectives. J Neurol Sci 2007 Jun 15;257(1–2):38–43.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">6. Mochida H, Kikuchi T, Tanaka H, Ikeda A, Fujii Y, Sasamura T, et al. Influence of Actovegin containing infusion solutions on wound healing and function of the intestinal tract in rats. Pharmacol Ther 1989;17:789–97.</mixed-citation><mixed-citation xml:lang="ru">Mochida H, Kikuchi T, Tanaka H, Ikeda A, Fujii Y, Sasamura T, et al. Influence of Actovegin containing infusion solutions on wound healing and function of the intestinal tract in rats. Pharmacol Ther 1989;17:789–97.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">7. Schonwald D, Sixt B, Machicao F, Marx E, Haedenkamp G, Bertsch S. Enhanced proliferation of coronary endothelial cells in response to growth factors is synergized by hemodialysate compounds in vitro. Res Exp Med (Berl) 1991;191(4):259–72.</mixed-citation><mixed-citation xml:lang="ru">Schonwald D, Sixt B, Machicao F, Marx E, Haedenkamp G, Bertsch S. Enhanced proliferation of coronary endothelial cells in response to growth factors is synergized by hemodialysate compounds in vitro. Res Exp Med (Berl) 1991;191(4):259–72.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">8. Basu SK, Srinivasan MN, Chuttani K, Ghose A. Evaluation of some radioprotectors by the survival study of rats exposed to lethal dose of whole body gamma radiation. J Radiat Res (Tokyo) 1985 Dec;26(4): 395–403.</mixed-citation><mixed-citation xml:lang="ru">Basu SK, Srinivasan MN, Chuttani K, Ghose A. Evaluation of some radioprotectors by the survival study of rats exposed to lethal dose of whole body gamma radiation. J Radiat Res (Tokyo) 1985 Dec;26(4): 395–403.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">9. Hegner N. Wirkung eines deproteinisierten Hämoderivates (Actovegin) im induzierten hypovolämischen Schock unter besonderen Berücksichtigung des Energiestoffwechsels. Johannes-Gutenberg Universität Mainz: Institut für Anästhesiologie; 1983.</mixed-citation><mixed-citation xml:lang="ru">Hegner N. Wirkung eines deproteinisierten Hämoderivates (Actovegin) im induzierten hypovolämischen Schock unter besonderen Berücksichtigung des Energiestoffwechsels. Johannes-Gutenberg Universität Mainz: Institut für Anästhesiologie; 1983.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">10. Giarola P. Effects of blood extract on plasma lipids, blood coagulation, fibrinolysis, and platelet aggregation in experimental hypercholesterolemia of rabbits. Arzneim-Forsch 1974;24:925–8.</mixed-citation><mixed-citation xml:lang="ru">Giarola P. Effects of blood extract on plasma lipids, blood coagulation, fibrinolysis, and platelet aggregation in experimental hypercholesterolemia of rabbits. Arzneim-Forsch 1974;24:925–8.</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">11. Elmlinger MW, Kriebel M, Ziegler D. Neuroprotective and anti-oxidative effects of the hemodialysate actovegin on primary rat neurons in vitro. Neuromolecular Med 2011 Dec;13(4):266–74.</mixed-citation><mixed-citation xml:lang="ru">Elmlinger MW, Kriebel M, Ziegler D. Neuroprotective and anti-oxidative effects of the hemodialysate actovegin on primary rat neurons in vitro. Neuromolecular Med 2011 Dec;13(4):266–74.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">12. Dieckmann A, Kriebel M, Andriambeloson E, Ziegler D, Elmlinger M. Treatment with Actovegin® improves sensory nerve function and pathology in streptozotocin- diabetic rats via mechanisms involving inhibition of PARP activation. Exp Clin Endocrinol Diabetes 2011 Oct 21;120(3):132–8.</mixed-citation><mixed-citation xml:lang="ru">Dieckmann A, Kriebel M, Andriambeloson E, Ziegler D, Elmlinger M. Treatment with Actovegin® improves sensory nerve function and pathology in streptozotocin- diabetic rats via mechanisms involving inhibition of PARP activation. Exp Clin Endocrinol Diabetes 2011 Oct 21;120(3):132–8.</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">13. Kuninaka T, Senga Y, Senga H, Weiner M. Nature of enhanced mitochondrial oxidative metabolism by a calf blood extract. J Cell Physiol 1991 Jan;146(1):148–55.</mixed-citation><mixed-citation xml:lang="ru">Kuninaka T, Senga Y, Senga H, Weiner M. Nature of enhanced mitochondrial oxidative metabolism by a calf blood extract. J Cell Physiol 1991 Jan;146(1):148–55.</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">14. Buchmayer F, Pleiner J, Elmlinger MW, Lauer G, Nell G, Sitte HH. Actovegin®: a biological drug for more than 5 decades. Wien Med Wochenschr 2011 Feb; 161(3–4):80–8.</mixed-citation><mixed-citation xml:lang="ru">Buchmayer F, Pleiner J, Elmlinger MW, Lauer G, Nell G, Sitte HH. Actovegin®: a biological drug for more than 5 decades. Wien Med Wochenschr 2011 Feb; 161(3–4):80–8.</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">15. Bachmann W, Forster H, Mehnert H. Experimental studies in animals on the effect of a protein-free blood extract on the metabolism of glucose. Arzneim-Forsch 1968;18:1023–7.</mixed-citation><mixed-citation xml:lang="ru">Bachmann W, Forster H, Mehnert H. Experimental studies in animals on the effect of a protein-free blood extract on the metabolism of glucose. Arzneim-Forsch 1968;18:1023–7.</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">16. Rao J, Oz G, Seaquist ER. Regulation of cerebral glucose metabolism. Minerva Endocrinol 2006 Jun;31(2):149–58.</mixed-citation><mixed-citation xml:lang="ru">Rao J, Oz G, Seaquist ER. Regulation of cerebral glucose metabolism. Minerva Endocrinol 2006 Jun;31(2):149–58.</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">17. McEwen BS, Reagan LP. Glucose transporter expression in the central nervous system: relationship to synaptic function. Eur J Pharmacol 2004 Apr 19;490(1–3): 13–24.</mixed-citation><mixed-citation xml:lang="ru">McEwen BS, Reagan LP. Glucose transporter expression in the central nervous system: relationship to synaptic function. Eur J Pharmacol 2004 Apr 19;490(1–3): 13–24.</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">18. Grillo CA, Piroli GG, Hendry RM, Reagan LP. Insulin-stimulated translocation of GLUT4 to the plasma membrane in rat hippocampus is PI3-kinase dependent. Brain Res 2009 Nov 3;1296:35–45.</mixed-citation><mixed-citation xml:lang="ru">Grillo CA, Piroli GG, Hendry RM, Reagan LP. Insulin-stimulated translocation of GLUT4 to the plasma membrane in rat hippocampus is PI3-kinase dependent. Brain Res 2009 Nov 3;1296:35–45.</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">19. Kobayashi M, Nikami H, Morimatsu M, Saito M. Expression and localization of insulin-regulatable glucose transporter (GLUT4) in rat brain. Neurosci Lett 1996 Aug 2;213(2):103–6.</mixed-citation><mixed-citation xml:lang="ru">Kobayashi M, Nikami H, Morimatsu M, Saito M. Expression and localization of insulin-regulatable glucose transporter (GLUT4) in rat brain. Neurosci Lett 1996 Aug 2;213(2):103–6.</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">20. Pardridge WM, Oldendorf WH, Cancilla P, Frank HJ. Blood–brain barrier: interface between internal medicine and the brain. Ann Intern Med 1986 Jul;105(1):82–95.</mixed-citation><mixed-citation xml:lang="ru">Pardridge WM, Oldendorf WH, Cancilla P, Frank HJ. Blood–brain barrier: interface between internal medicine and the brain. Ann Intern Med 1986 Jul;105(1):82–95.</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">21. Zhao WQ, Chen H, Quon MJ, Alkon DL. Insulin and the insulin receptor in experimental models of learning and memory. Eur J Pharmacol 2004 Apr 19;490(1–3):71–81.</mixed-citation><mixed-citation xml:lang="ru">Zhao WQ, Chen H, Quon MJ, Alkon DL. Insulin and the insulin receptor in experimental models of learning and memory. Eur J Pharmacol 2004 Apr 19;490(1–3):71–81.</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">22. Nitsch R, Hoyer S. Local action of the diabetogenic drug, streptozotocin, on glucose and energy metabolism in rat brain cortex. Neurosci Lett 1991 Jul 22;128(2):199–202.</mixed-citation><mixed-citation xml:lang="ru">Nitsch R, Hoyer S. Local action of the diabetogenic drug, streptozotocin, on glucose and energy metabolism in rat brain cortex. Neurosci Lett 1991 Jul 22;128(2):199–202.</mixed-citation></citation-alternatives></ref><ref id="B23"><label>23.</label><citation-alternatives><mixed-citation xml:lang="en">23. Ding A, Nemeth G, Hoyer S. Age influences abnormalities in striatal dopamine metabolism during and after transient forebrain ischemia. J Neural Transm Park Dis Dement Sect 1992;4(3):213–25.</mixed-citation><mixed-citation xml:lang="ru">Ding A, Nemeth G, Hoyer S. Age influences abnormalities in striatal dopamine metabolism during and after transient forebrain ischemia. J Neural Transm Park Dis Dement Sect 1992;4(3):213–25.</mixed-citation></citation-alternatives></ref><ref id="B24"><label>24.</label><citation-alternatives><mixed-citation xml:lang="en">24. Lannert H, Hoyer S. Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats. Behav Neurosci 1998 Oct;112(5):1199–208.</mixed-citation><mixed-citation xml:lang="ru">Lannert H, Hoyer S. Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats. Behav Neurosci 1998 Oct;112(5):1199–208.</mixed-citation></citation-alternatives></ref><ref id="B25"><label>25.</label><citation-alternatives><mixed-citation xml:lang="en">25. Salkovic-Petrisic M, Hoyer S. Central insulin resistance as a trigger for sporadic Alzheimer-like pathology: an experimental approach. J Neural Transm Suppl 2007;72:217–33.</mixed-citation><mixed-citation xml:lang="ru">Salkovic-Petrisic M, Hoyer S. Central insulin resistance as a trigger for sporadic Alzheimer-like pathology: an experimental approach. J Neural Transm Suppl 2007;72:217–33.</mixed-citation></citation-alternatives></ref><ref id="B26"><label>26.</label><citation-alternatives><mixed-citation xml:lang="en">26. Machicao F, Mühlbacher C, Haring H. Inositol phospho-oligosaccharides from a dialysate (Actovegin) obtained from blood mimic the effect of lipogenesis glucose transport and lipolysis in rat adipocytes. Akt Endokr Stoffw 1989;10:111.</mixed-citation><mixed-citation xml:lang="ru">Machicao F, Mühlbacher C, Haring H. Inositol phospho-oligosaccharides from a dialysate (Actovegin) obtained from blood mimic the effect of lipogenesis glucose transport and lipolysis in rat adipocytes. Akt Endokr Stoffw 1989;10:111.</mixed-citation></citation-alternatives></ref><ref id="B27"><label>27.</label><citation-alternatives><mixed-citation xml:lang="en">27. Kellerer M, Machicao F, Berti L, Sixt B, Mushack J, Seffer E, et al. Inositol phosphooligosaccharides from rat fibroblasts and adipocytes stimulate 3-O-methylglucose transport. Biochem J 1993 Nov 1;295 (Pt 3):699–704.</mixed-citation><mixed-citation xml:lang="ru">Kellerer M, Machicao F, Berti L, Sixt B, Mushack J, Seffer E, et al. Inositol phosphooligosaccharides from rat fibroblasts and adipocytes stimulate 3-O-methylglucose transport. Biochem J 1993 Nov 1;295 (Pt 3):699–704.</mixed-citation></citation-alternatives></ref><ref id="B28"><label>28.</label><citation-alternatives><mixed-citation xml:lang="en">28. Reichel H, Weiss C, Leichtweiss HP. The effects of a blood extract on the oxygen uptake of isolated artificially perfused kidneys and skeletal muscles in rats. Arzneim-Forsch 1965;15(756):757.</mixed-citation><mixed-citation xml:lang="ru">Reichel H, Weiss C, Leichtweiss HP. The effects of a blood extract on the oxygen uptake of isolated artificially perfused kidneys and skeletal muscles in rats. Arzneim-Forsch 1965;15(756):757.</mixed-citation></citation-alternatives></ref><ref id="B29"><label>29.</label><citation-alternatives><mixed-citation xml:lang="en">29. de Groot H, Brecht M, Machicao F. Evidence for a factor protective against hypoxic liver parenchymal cell injury in a protein-free blood extract. Res Commun Chem Pathol Pharmacol Apr. 1990;68(1):125–8.</mixed-citation><mixed-citation xml:lang="ru">de Groot H, Brecht M, Machicao F. Evidence for a factor protective against hypoxic liver parenchymal cell injury in a protein-free blood extract. Res Commun Chem Pathol Pharmacol Apr. 1990;68(1):125–8.</mixed-citation></citation-alternatives></ref><ref id="B30"><label>30.</label><citation-alternatives><mixed-citation xml:lang="en">30. Hoyer S, Betz K. Elimination of the delayed postischemic energy deficit in cerebral cortex and hippocampus of aged rats with a dried, deproteinized blood extract (Actovegin). Arch Gerontol Geriatr 1989 Sep;9(2):181–92.</mixed-citation><mixed-citation xml:lang="ru">Hoyer S, Betz K. Elimination of the delayed postischemic energy deficit in cerebral cortex and hippocampus of aged rats with a dried, deproteinized blood extract (Actovegin). Arch Gerontol Geriatr 1989 Sep;9(2):181–92.</mixed-citation></citation-alternatives></ref><ref id="B31"><label>31.</label><citation-alternatives><mixed-citation xml:lang="en">31. Murakami K, Shimizu T, Irie K. Formation of the 42-mer amyloid beta radical and the therapeutic role of superoxide dismutase in Alzheimer's disease. J Amino Acids 2011;2011:654207.</mixed-citation><mixed-citation xml:lang="ru">Murakami K, Shimizu T, Irie K. Formation of the 42-mer amyloid beta radical and the therapeutic role of superoxide dismutase in Alzheimer's disease. J Amino Acids 2011;2011:654207.</mixed-citation></citation-alternatives></ref><ref id="B32"><label>32.</label><citation-alternatives><mixed-citation xml:lang="en">32. Zhang XH, Yu HL, Xiao R, Xiang L, Li L, Ma WW, et al. Neurotoxicity of betaamyloid peptide 31–35 and 25–35 to cultured rat cortical neurons. Zhonghua Yu Fang Yi Xue Za Zhi 2009 Dec;43(12): 1081–5.</mixed-citation><mixed-citation xml:lang="ru">Zhang XH, Yu HL, Xiao R, Xiang L, Li L, Ma WW, et al. Neurotoxicity of betaamyloid peptide 31–35 and 25–35 to cultured rat cortical neurons. Zhonghua Yu Fang Yi Xue Za Zhi 2009 Dec;43(12): 1081–5.</mixed-citation></citation-alternatives></ref><ref id="B33"><label>33.</label><citation-alternatives><mixed-citation xml:lang="en">33. Pike CJ, Walencewicz-Wasserman AJ, Kosmoski J, Cribbs DH, Glabe CG, Cotman CW. Structure-activity analyses of beta-amyloid peptides: contributions of the beta 25–35 region to aggregation and neurotoxicity. J Neurochem 1995 Jan;64(1): 253-65.</mixed-citation><mixed-citation xml:lang="ru">Pike CJ, Walencewicz-Wasserman AJ, Kosmoski J, Cribbs DH, Glabe CG, Cotman CW. Structure-activity analyses of beta-amyloid peptides: contributions of the beta 25–35 region to aggregation and neurotoxicity. J Neurochem 1995 Jan;64(1): 253-65.</mixed-citation></citation-alternatives></ref><ref id="B34"><label>34.</label><citation-alternatives><mixed-citation xml:lang="en">34. Millucci L, Raggiaschi R, Franceschini D, Terstappen G, Santucci A. Rapid aggregation and assembly in aqueous solution of A beta (25–35) peptide. J Biosci 2009 Jun;34(2):293–303.</mixed-citation><mixed-citation xml:lang="ru">Millucci L, Raggiaschi R, Franceschini D, Terstappen G, Santucci A. Rapid aggregation and assembly in aqueous solution of A beta (25–35) peptide. J Biosci 2009 Jun;34(2):293–303.</mixed-citation></citation-alternatives></ref><ref id="B35"><label>35.</label><citation-alternatives><mixed-citation xml:lang="en">35. Trubetskaya VV, Stepanichev MY, Onufriev MV, Lazareva NA, Markevich VA, Gulyaeva NV. Administration of aggregated beta-amyloid peptide (25–35) induces changes in long-term potentiation in the hippocampus in vivo. Neurosci Behav Physiol 2003 Feb;33(2):95–8.</mixed-citation><mixed-citation xml:lang="ru">Trubetskaya VV, Stepanichev MY, Onufriev MV, Lazareva NA, Markevich VA, Gulyaeva NV. Administration of aggregated beta-amyloid peptide (25–35) induces changes in long-term potentiation in the hippocampus in vivo. Neurosci Behav Physiol 2003 Feb;33(2):95–8.</mixed-citation></citation-alternatives></ref><ref id="B36"><label>36.</label><citation-alternatives><mixed-citation xml:lang="en">36. Klementiev B, Novikova T, Novitskaya V, Walmod PS, Dmytriyeva O, Pakkenberg B, et al. A neural cell adhesion moleculederived peptide reduces neuropathological signs and cognitive impairment induced by Abeta25–35. Neuroscience 2007 Mar 2; 145(1):209–24.</mixed-citation><mixed-citation xml:lang="ru">Klementiev B, Novikova T, Novitskaya V, Walmod PS, Dmytriyeva O, Pakkenberg B, et al. A neural cell adhesion moleculederived peptide reduces neuropathological signs and cognitive impairment induced by Abeta25–35. Neuroscience 2007 Mar 2; 145(1):209–24.</mixed-citation></citation-alternatives></ref><ref id="B37"><label>37.</label><citation-alternatives><mixed-citation xml:lang="en">37. Kubo T, Nishimura S, Kumagae Y, Kaneko I. In vivo conversion of racemized beta-amyloid ([D-Ser 26]A beta 1–40) to truncated and toxic fragments ([D-Ser 26] A beta 25–35/40) and fragment presence in the brains of Alzheimer's patients. J Neurosci Res 2002 Nov 1;70(3):474–83.</mixed-citation><mixed-citation xml:lang="ru">Kubo T, Nishimura S, Kumagae Y, Kaneko I. In vivo conversion of racemized beta-amyloid ([D-Ser 26]A beta 1–40) to truncated and toxic fragments ([D-Ser 26] A beta 25–35/40) and fragment presence in the brains of Alzheimer's patients. J Neurosci Res 2002 Nov 1;70(3):474–83.</mixed-citation></citation-alternatives></ref><ref id="B38"><label>38.</label><citation-alternatives><mixed-citation xml:lang="en">38. Meffert MK, Chang JM, Wiltgen BJ, Fanselow MS, Baltimore D. NF-kappa B functions in synaptic signaling and behavior. Nat Neurosci 2003 Oct;6(10):1072–8.</mixed-citation><mixed-citation xml:lang="ru">Meffert MK, Chang JM, Wiltgen BJ, Fanselow MS, Baltimore D. NF-kappa B functions in synaptic signaling and behavior. Nat Neurosci 2003 Oct;6(10):1072–8.</mixed-citation></citation-alternatives></ref><ref id="B39"><label>39.</label><citation-alternatives><mixed-citation xml:lang="en">39. Kaltschmidt B, Kaltschmidt C. NFkappa B in the nervous system. Cold Spring Harb Perspect Biol 2009 Sep;1(3):a001271.</mixed-citation><mixed-citation xml:lang="ru">Kaltschmidt B, Kaltschmidt C. NFkappa B in the nervous system. Cold Spring Harb Perspect Biol 2009 Sep;1(3):a001271.</mixed-citation></citation-alternatives></ref><ref id="B40"><label>40.</label><citation-alternatives><mixed-citation xml:lang="en">40. Kaltschmidt B, Uherek M, Wellmann H, Volk B, Kaltschmidt C. Inhibition of NFkappa B potentiates amyloid beta-mediated neuronal apoptosis. Proc Natl Acad Sci USA 1999 Aug 3;96(16):9409–14.</mixed-citation><mixed-citation xml:lang="ru">Kaltschmidt B, Uherek M, Wellmann H, Volk B, Kaltschmidt C. Inhibition of NFkappa B potentiates amyloid beta-mediated neuronal apoptosis. Proc Natl Acad Sci USA 1999 Aug 3;96(16):9409–14.</mixed-citation></citation-alternatives></ref><ref id="B41"><label>41.</label><citation-alternatives><mixed-citation xml:lang="en">41. Meunier A, Latremoliere A, Dominguez E, Mauborgne A, Philippe S, Hamon M, et al. Lentiviral-mediated targeted NF-kappa B blockade in dorsal spinal cord glia attenuates sciatic nerve injury-induced neuropathic pain in the rat. Mol Ther 2007 Apr;15(4):687–97.</mixed-citation><mixed-citation xml:lang="ru">Meunier A, Latremoliere A, Dominguez E, Mauborgne A, Philippe S, Hamon M, et al. Lentiviral-mediated targeted NF-kappa B blockade in dorsal spinal cord glia attenuates sciatic nerve injury-induced neuropathic pain in the rat. Mol Ther 2007 Apr;15(4):687–97.</mixed-citation></citation-alternatives></ref><ref id="B42"><label>42.</label><citation-alternatives><mixed-citation xml:lang="en">42. Mattson MP, Meffert MK. Roles for NF-kappa B in nerve cell survival, plasticity, and disease. Cell Death Differ 2006 May;13(5):852–60.</mixed-citation><mixed-citation xml:lang="ru">Mattson MP, Meffert MK. Roles for NF-kappa B in nerve cell survival, plasticity, and disease. Cell Death Differ 2006 May;13(5):852–60.</mixed-citation></citation-alternatives></ref><ref id="B43"><label>43.</label><citation-alternatives><mixed-citation xml:lang="en">43. Tamatani M, Che YH, Matsuzaki H, Ogawa S, Okado H, Miyake S, et al. Tumor necrosis factor induces Bcl-2 and Bcl-x expression through NFkappa B activation in primary hippocampal neurons. J Biol Chem 1999 Mar 26;274(13):8531–8.</mixed-citation><mixed-citation xml:lang="ru">Tamatani M, Che YH, Matsuzaki H, Ogawa S, Okado H, Miyake S, et al. Tumor necrosis factor induces Bcl-2 and Bcl-x expression through NFkappa B activation in primary hippocampal neurons. J Biol Chem 1999 Mar 26;274(13):8531–8.</mixed-citation></citation-alternatives></ref><ref id="B44"><label>44.</label><citation-alternatives><mixed-citation xml:lang="en">44. Kenchappa P, Yadav A, Singh G, Nandana S, Banerjee K. Rescue of TNFalpha-inhibited neuronal cells by IGF-1 involves Akt and c-Jun N-terminal kinases. J Neurosci Res 2004 May 15;76(4):466–74.</mixed-citation><mixed-citation xml:lang="ru">Kenchappa P, Yadav A, Singh G, Nandana S, Banerjee K. Rescue of TNFalpha-inhibited neuronal cells by IGF-1 involves Akt and c-Jun N-terminal kinases. J Neurosci Res 2004 May 15;76(4):466–74.</mixed-citation></citation-alternatives></ref><ref id="B45"><label>45.</label><citation-alternatives><mixed-citation xml:lang="en">45. Waetzig GH, Rosenstiel P, Arlt A, Till A, Brautigam K, Schafer H, et al. Soluble tumor necrosis factor (TNF) receptor-1 induces apoptosis via reverse TNF signaling and autocrine transforming growth factorbeta1. FASEB J 2005 Jan;19(1):91–3.</mixed-citation><mixed-citation xml:lang="ru">Waetzig GH, Rosenstiel P, Arlt A, Till A, Brautigam K, Schafer H, et al. Soluble tumor necrosis factor (TNF) receptor-1 induces apoptosis via reverse TNF signaling and autocrine transforming growth factorbeta1. FASEB J 2005 Jan;19(1):91–3.</mixed-citation></citation-alternatives></ref><ref id="B46"><label>46.</label><citation-alternatives><mixed-citation xml:lang="en">46. Nawashiro H, Tasaki K, Ruetzler CA, Hallenbeck JM. TNF-alpha pretreatment induces protective effects against focal cerebral ischemia in mice. J Cereb Blood Flow Metab 1997 May;17(5):483–90.</mixed-citation><mixed-citation xml:lang="ru">Nawashiro H, Tasaki K, Ruetzler CA, Hallenbeck JM. TNF-alpha pretreatment induces protective effects against focal cerebral ischemia in mice. J Cereb Blood Flow Metab 1997 May;17(5):483–90.</mixed-citation></citation-alternatives></ref><ref id="B47"><label>47.</label><citation-alternatives><mixed-citation xml:lang="en">47. Bruce AJ, Boling W, Kindy MS, Peschon J, Kraemer PJ, Carpenter MK, et al. Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors. Nat Med 1996 Jul;2(7):788–94.</mixed-citation><mixed-citation xml:lang="ru">Bruce AJ, Boling W, Kindy MS, Peschon J, Kraemer PJ, Carpenter MK, et al. Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors. Nat Med 1996 Jul;2(7):788–94.</mixed-citation></citation-alternatives></ref><ref id="B48"><label>48.</label><citation-alternatives><mixed-citation xml:lang="en">48. Arnett HA, Mason J, Marino M, Suzuki K, Matsushima GK, Ting JP. TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nat Neurosci 2001 Nov;4(11):1116–22.</mixed-citation><mixed-citation xml:lang="ru">Arnett HA, Mason J, Marino M, Suzuki K, Matsushima GK, Ting JP. TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nat Neurosci 2001 Nov;4(11):1116–22.</mixed-citation></citation-alternatives></ref><ref id="B49"><label>49.</label><citation-alternatives><mixed-citation xml:lang="en">49. Barger SW, Horster D, Furukawa K, Goodman Y, Krieglstein J, Mattson MP. Tumor necrosis factors alpha and beta protect neurons against amyloid betapeptide toxicity: evidence for involvement of a kappa B-binding factor and attenuation of peroxide and Ca2+ accumulation. Proc Natl Acad Sci USA 1995 Sep 26;92(20):9328–32.</mixed-citation><mixed-citation xml:lang="ru">Barger SW, Horster D, Furukawa K, Goodman Y, Krieglstein J, Mattson MP. Tumor necrosis factors alpha and beta protect neurons against amyloid betapeptide toxicity: evidence for involvement of a kappa B-binding factor and attenuation of peroxide and Ca2+ accumulation. Proc Natl Acad Sci USA 1995 Sep 26;92(20):9328–32.</mixed-citation></citation-alternatives></ref><ref id="B50"><label>50.</label><citation-alternatives><mixed-citation xml:lang="en">50. Kaltschmidt C, Kaltschmidt B, Neumann H, Wekerle H, Baeuerle PA. Constitutive NF-kappa B activity</mixed-citation><mixed-citation xml:lang="ru">Kaltschmidt C, Kaltschmidt B, Neumann H, Wekerle H, Baeuerle PA. Constitutive NF-kappa B activity</mixed-citation></citation-alternatives></ref><ref id="B51"><label>51.</label><mixed-citation>in neurons. Mol Cell Biol 1994 Jun;14(6):3981–92.</mixed-citation></ref><ref id="B52"><label>52.</label><citation-alternatives><mixed-citation xml:lang="en">51. Pieper AA, Verma A, Zhang J, Snyder SH. Poly (ADP-ribose) polymerase, nitric oxide and cell death. Trends Pharmacol Sci 1999 Apr;20(4):171–81.</mixed-citation><mixed-citation xml:lang="ru">Pieper AA, Verma A, Zhang J, Snyder SH. Poly (ADP-ribose) polymerase, nitric oxide and cell death. Trends Pharmacol Sci 1999 Apr;20(4):171–81.</mixed-citation></citation-alternatives></ref><ref id="B53"><label>53.</label><citation-alternatives><mixed-citation xml:lang="en">52. Eliasson MJ, Sampei K, Mandir AS, Hurn PD, Traystman RJ, Bao J, et al. Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia. Nat Med 1997 Oct;3(10):1089–95.</mixed-citation><mixed-citation xml:lang="ru">Eliasson MJ, Sampei K, Mandir AS, Hurn PD, Traystman RJ, Bao J, et al. Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia. Nat Med 1997 Oct;3(10):1089–95.</mixed-citation></citation-alternatives></ref><ref id="B54"><label>54.</label><citation-alternatives><mixed-citation xml:lang="en">53. Burkart V, Wang ZQ, Radons J, Heller B, Herceg Z, Stingl L, et al. Mice lacking the poly(ADP-ribose) polymerase gene are resistant to pancreatic beta-cell destruction and diabetes development induced by streptozocin. Nat Med 1999 Mar;5(3):314–9.</mixed-citation><mixed-citation xml:lang="ru">Burkart V, Wang ZQ, Radons J, Heller B, Herceg Z, Stingl L, et al. Mice lacking the poly(ADP-ribose) polymerase gene are resistant to pancreatic beta-cell destruction and diabetes development induced by streptozocin. Nat Med 1999 Mar;5(3):314–9.</mixed-citation></citation-alternatives></ref><ref id="B55"><label>55.</label><citation-alternatives><mixed-citation xml:lang="en">54. Pieper AA, Brat DJ, Krug DK, Watkins CC, Gupta A, Blackshaw S, et al. Poly(ADP-ribose) polymerase-deficient mice are protected from streptozotocininduced diabetes. Proc Natl Acad Sci USA 1999 Mar 16;96(6):3059–64.</mixed-citation><mixed-citation xml:lang="ru">Pieper AA, Brat DJ, Krug DK, Watkins CC, Gupta A, Blackshaw S, et al. Poly(ADP-ribose) polymerase-deficient mice are protected from streptozotocininduced diabetes. Proc Natl Acad Sci USA 1999 Mar 16;96(6):3059–64.</mixed-citation></citation-alternatives></ref><ref id="B56"><label>56.</label><citation-alternatives><mixed-citation xml:lang="en">55. Garcia SF, Virag L, Jagtap P, Szabo E, Mabley JG, Liaudet L, et al. Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nat Med 2001 Jan;7(1):108–13.</mixed-citation><mixed-citation xml:lang="ru">Garcia SF, Virag L, Jagtap P, Szabo E, Mabley JG, Liaudet L, et al. Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nat Med 2001 Jan;7(1):108–13.</mixed-citation></citation-alternatives></ref><ref id="B57"><label>57.</label><citation-alternatives><mixed-citation xml:lang="en">56. Ilnytska O, Lyzogubov VV, Stevens MJ, Drel VR, Mashtalir N, Pacher P, et al. Poly(ADP-ribose) polymerase inhibition alleviates experimental diabetic sensory neuropathy. Diabetes 2006 Jun;55(6): 1686–94.</mixed-citation><mixed-citation xml:lang="ru">Ilnytska O, Lyzogubov VV, Stevens MJ, Drel VR, Mashtalir N, Pacher P, et al. Poly(ADP-ribose) polymerase inhibition alleviates experimental diabetic sensory neuropathy. Diabetes 2006 Jun;55(6): 1686–94.</mixed-citation></citation-alternatives></ref></ref-list></back></article>
